577 related articles for article (PubMed ID: 24312913)
1. A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer.
Karami F; Mehdipour P
Biomed Res Int; 2013; 2013():928562. PubMed ID: 24312913
[TBL] [Abstract][Full Text] [Related]
2. Frequency and spectrum of founder and non-founder BRCA1 and BRCA2 mutations in a large series of Russian breast cancer and ovarian cancer patients.
Sokolenko AP; Sokolova TN; Ni VI; Preobrazhenskaya EV; Iyevleva AG; Aleksakhina SN; Romanko AA; Bessonov AA; Gorodnova TV; Anisimova EI; Savonevich EL; Bizin IV; Stepanov IA; Krivorotko PV; Berlev IV; Belyaev AM; Togo AV; Imyanitov EN
Breast Cancer Res Treat; 2020 Nov; 184(1):229-235. PubMed ID: 32776218
[TBL] [Abstract][Full Text] [Related]
3. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC
JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive mutational analysis of BRCA1/BRCA2 for Korean breast cancer patients: evidence of a founder mutation.
Seong MW; Cho S; Noh DY; Han W; Kim SW; Park CM; Park HW; Kim SY; Kim JY; Park SS
Clin Genet; 2009 Aug; 76(2):152-60. PubMed ID: 19656164
[TBL] [Abstract][Full Text] [Related]
5. BRCA1 and BRCA2 mutation analysis in breast-ovarian cancer families from northeastern Poland.
Perkowska M; BroZek I; Wysocka B; Haraldsson K; Sandberg T; Johansson U; Sellberg G; Borg A; Limon J
Hum Mutat; 2003 May; 21(5):553-4. PubMed ID: 12673801
[TBL] [Abstract][Full Text] [Related]
6. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
Hamel N; Kotar K; Foulkes WD
BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
[TBL] [Abstract][Full Text] [Related]
7. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.
Cierniková S; Tomka M; Kovác M; Stevurková V; Zajac V
Neoplasma; 2006; 53(2):97-102. PubMed ID: 16575464
[TBL] [Abstract][Full Text] [Related]
8. Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women.
Comen E; Davids M; Kirchhoff T; Hudis C; Offit K; Robson M
Breast Cancer Res Treat; 2011 Aug; 129(1):185-90. PubMed ID: 21394499
[TBL] [Abstract][Full Text] [Related]
9. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women.
Abeliovich D; Kaduri L; Lerer I; Weinberg N; Amir G; Sagi M; Zlotogora J; Heching N; Peretz T
Am J Hum Genet; 1997 Mar; 60(3):505-14. PubMed ID: 9042909
[TBL] [Abstract][Full Text] [Related]
10. Comparing the frequency of common genetic variants and haplotypes between carriers and non-carriers of BRCA1 and BRCA2 deleterious mutations in Australian women diagnosed with breast cancer before 40 years of age.
Turkovic L; Gurrin LC; Bahlo M; Dite GS; Southey MC; Hopper JL
BMC Cancer; 2010 Sep; 10():466. PubMed ID: 20807450
[TBL] [Abstract][Full Text] [Related]
11. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.
Riedlova P; Janoutova J; Hermanova B
Mol Biol Rep; 2020 Apr; 47(4):2763-2769. PubMed ID: 32180084
[TBL] [Abstract][Full Text] [Related]
12. BRCA1/2 germline mutations and their clinical importance in Turkish breast cancer patients.
Cecener G; Egeli U; Tunca B; Erturk E; Ak S; Gokgoz S; Tasdelen I; Tezcan G; Demirdogen E; Bayram N; Avci N; Evrensel T
Cancer Invest; 2014 Oct; 32(8):375-87. PubMed ID: 24884828
[TBL] [Abstract][Full Text] [Related]
13. Next-Generation Sequencing Identifies
Peker Eyüboğlu İ; Yenmiş G; Bingöl EN; Yüksel Ş; Tokat F; Özbek P; Güllü Amuran G; Yakıcıer C; Akkiprik M
OMICS; 2020 Jan; 24(1):5-15. PubMed ID: 31851867
[TBL] [Abstract][Full Text] [Related]
14. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
[TBL] [Abstract][Full Text] [Related]
15. [Genotyping of BRCA1, BRCA2 and CHEK2 germline mutations in Russian breast cancer patients using diagnostic biochips].
Nasedkina TV; Gromyko OE; Emel'ianova MA; Ignatova EO; Kazubskaia TP; Portnoĭ SM; Zasedatelev AS; Liubchenko LN
Mol Biol (Mosk); 2014; 48(2):243-50. PubMed ID: 25850293
[TBL] [Abstract][Full Text] [Related]
16. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.
Levy-Lahad E; Catane R; Eisenberg S; Kaufman B; Hornreich G; Lishinsky E; Shohat M; Weber BL; Beller U; Lahad A; Halle D
Am J Hum Genet; 1997 May; 60(5):1059-67. PubMed ID: 9150153
[TBL] [Abstract][Full Text] [Related]
17. BRCA1 c.5470_5477del, a founder mutation in Chinese Han breast cancer patients.
Meng H; Yao L; Yuan H; Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Int J Cancer; 2020 Jun; 146(11):3044-3052. PubMed ID: 31957001
[TBL] [Abstract][Full Text] [Related]
18. BRCA1/BRCA2 founder mutations and cancer risks: impact in the western Danish population.
Nielsen HR; Nilbert M; Petersen J; Ladelund S; Thomassen M; Pedersen IS; Hansen TV; Skytte AB; Borg Å; Therkildsen C
Fam Cancer; 2016 Oct; 15(4):507-12. PubMed ID: 26833046
[TBL] [Abstract][Full Text] [Related]
19. Familial breast cancer: double heterozygosity for BRCA1 and BRCA2 mutations with differing phenotypes.
Smith M; Fawcett S; Sigalas E; Bell R; Devery S; Andrieska N; Winship I
Fam Cancer; 2008; 7(2):119-24. PubMed ID: 17636421
[TBL] [Abstract][Full Text] [Related]
20.
Kharel S; Shrestha S; Yadav S; Shakya P; Baidya S; Hirachan S
J Int Med Res; 2022 Jan; 50(1):3000605211070757. PubMed ID: 35000471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
